

Supporting Information

Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

Caolin Wang [†], Shan Xu[†], Liang Peng, Bingliang Zhang, Hong Zhang, Yingying Hu, Pengwu Zheng*,
Wufu Zhu*

*Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi
Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi 330013, China*


[†] These authors contribute equally to this work

*To whom correspondence should be addressed. zhuwufu-1122@163.com(W.Zhu),
zhengpw@126.com (P. Zheng)


Contents

Compound characterization


14: ^1H NMR




14: ^{13}C NMR




18: ¹H NMR




28: ¹H NMR




34: ¹H NMR




37: ¹H NMR




38: ¹H NMR




39: ¹H NMR



41: ¹H NMR



47: ¹H NMR



51: ¹H NMR

